1[1]Slamon D J,Clark G M,Wong S G,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,1987,235:177-182.
2[2]Seshadri R,Firgaira FA,Horsfall D J,et al.Clinical significance of HER-2/neu oncogene amplification in primary breast caucer.The South Australia Breast Cancer Study Group.J Clin Oncol,1993,11:1936-1942.
3[3]Bianco A R,DeLaurentis M,Carlomagno C,et al.20 year update of the Naples GUN trial of adjuvant breast cancer therapy:evidence of interaction between C-erbB-2 expression and tsmoxifen efficacy//4th Annual ASCO Meeting.VA.Alexandria:ASCO Press Center,1998:373.
4[4]Ellis M J,Coop A,Singh B,et al.Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.Cancer Res,2003,63:6523-6531.
5[5]Muss H,Berry D,Thor A,et al.Lack of interaction of tamoxifen use and ERBb·2/neu(H)expression in CALGB8541:a randomized adjuvant trial of three diferent doses of CAF in node-positive breast cancer.Proc Am Soc Clin Oncol,1998,18:68.
6[6]Allied D C,Clark G M,Tandon A K,et al.HER-2/neu in node-negative breast cancer:prognostic significance of overexpression influenced by the prnsence of in situ carcinoma.J Ctin Oncol,1992,10:599-605.
7[7]Tanner M,Isola J,Wiklund T,et al.Topoisomerase Ⅱ alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthrax cycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:Scandinavian Breast Group Trial 9401.J Clin Oncol,2006,24:2428-2436.
8[8]Burstein H J,Harris L N.Gelman R,et al.Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyelophosphamide for HER-2 overexpressing stage Ⅱ orⅢbreast cancer:a pilot study.J Clin Oncol.2003.21:46-53.
9[9]Buzdar A U,Ibrah im N K,F rancis D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a random ized trial in human epidermal growth factor receptor 22 positive operable breast cancer.J Clin Oncol,2005,23:3676-3685.
10[10]Gianni L,Semiglazov V,Manikhas G M,et al.Neoadjuvant trastuzumab plus doxorubicin,pachtaxel and CMF in locally advanced breast cancet(NOAH trial):Feasibility,safety and antitumor effects//2007 Breast Cancer Symposium.VA,Alexandria:ASCO Press Center,2007:144.
3PEROU C M,SORLIE T,EISEN M B,et al. Molecular portraits of human breast tumours [J]. Nature,2000,406 (6797) : 747 - 752.
4GAREY L A,PEROU C M, LIVASY C A,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA,2006,295(21 ) :2492 - 2502.
5SORLIE T,PEROU C M,TIBSHIANI R,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [ J ]. Proc Natl Acad Sci USA ,2001,98(19) : 10869 - 10874.
6RAKHA E A, EI-REHIM D A, PAISH C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance [ J ]. Cancer,2006,42: 3149 - 3156.
7LANGEROD A,ZHOU H,BORGAN O,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer [J]. Breast Cancer Res, 2007,9:R30.
9ONITILO A A, ENGEL J M, GREENLEE R T, et al. Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathologic features and survival [J]. Clin Med Res,2009,7( 1-2):4 - 13.
10JAHANZEB M. Adjuvant/rastuzumab therapy for HER2- positive breast cancer [J]. Clin Breast Cancer,2008,8 (4) :324 - 333.
